Cytomegalovirus Infection Treatment Market elevates at a CAGR of 13.79% during 2020-2030, asserts DelveInsight

LAS VEGAS, Jan. 27, 2021 /PRNewswire/ -- DelveInsight's "Cytomegalovirus (CMV) Infection Market Report" report provides an absolute comprehension of the Cytomegalovirus Infection, historical and forecasted epidemiology and the CMV market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Cytomegalovirus market report also proffers an analysis of recent Cytomegalovirus treatment practice/algorithm, market drivers, market barriers and unmet medical needs. 

Some of the essential highlights of the Cytomegalovirus Therapeutics Market Research Report : 

• Increasing CMV Infections cases in various regions leads to increased demand for advanced diagnostics that, in turn, contribute to the CMV market growth. 
• The Cytomegalovirus Infection treatment market is divided into Prophylaxis and Therapeutic. Currently, the market is dominated by drugs like valganciclovir, valacyclovir hydrochloride, and others. However, the CMV market of these drugs will experience a plunge in market share due to the launch of new emerging therapies. 
• Cytomegalovirus Therapeutics Market anticipates the emergence of pipeline products namely V160 (Merck), mRNA-1647 (ModernaTX), HB-101/VaxWave (Hookipa Biotech), Triplex (Helocyte), Maribavir (TAK-602) (Takeda/Shire Pharmaceuticals), and Viralym-M (AlloVir). 
• One of the most promising anti-CMV drugs in clinical development is Maribavir (Shire). The drug is in phase III stage of development for the transplant cases with Cytomegalovirus Infections that are refractory or treatment-resistant, and also, for Cytomegalovirus (CMV) Infection Treatment in Hematopoietic Stem Cell Transplant Recipients.

For additional information on Market Impact by Therapies, visit: Global Cytomegalovirus Treatment Market Report 

Cytomegalovirus (CMV) Infection is a viral infection that rarely causes serious illness. Human CMV causes a broad variety of infection and illness in healthy adults, in those with compromised immune systems (such as AIDS), in those with cardiovascular disease, and in pregnant women who can pass the infection to their unborn child (congenital CMV). In 2020, the total of Cytomegalovirus diagnosed cases were found to be 111,959 cases in the 7MM. 

The Cytomegalovirus Infection Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total Diagnosed Cases of CMV Infection
• Number of Infants born with Congenital CMV
• CMV Patients among Hematopoietic Stem Cell Transplants (HSCT)
• Number of CMV Patients among Solid Organ Transplantation (SOT)
• Number of Refractory CMV Patients after HSCT/SOT
• CMV Retinitis among HIV Patients

Request for a free sample report for more insights @ CMV therapeutics market growth

Cytomegalovirus Infection Therapeutics Market Analysis 

The management of CMV infection is maintained by two approaches, i.e. prophylaxis and therapeutic approach. Currently, the global Cytomegalovirus treatment market is dominated by drugs like valganciclovir, valacyclovir hydrochloride, and others. However, the market of these drugs will experience a drop in the market share due to the launch of new emerging therapies. Recently, Prevymis (Letermovir) received FDA approval in 2017, to prevent Human Cytomegalovirus (HCMV) infection in transplant patients and entered the market in 2018. Prevymis covers a tiny targeted population because it is approved only for the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). 

Hence, it will positively impact the market size growth but will not be responsible for the major increase in the CMV market size. There is an estimated decline in its market after 2029, as the patent of prevymis will expire in 2029. Among the prophylactic potential market, two therapies, V160 and mRNA-1647, target the same patient population, CMV-seronegative and CMV-seropositive healthy adults (childbearing women) to prevent congenital CMV. Moreover, in the therapeutic potential market, it is believed that Maribavir can be a promising agent in the US for Cytomegalovirus Infection treatment.

In the United States, antiviral drugs are used for CMV infection following transplant procedures. The drugs include valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination. The US FDA and EMA support the CMV therapeutics pipeline by encouraging the drug development process through a different type of designations. 

Cytomegalovirus Infection Emerging Products Along with Key Players 

• Maribavir (TAK-602): Takeda/Shire Pharmaceuticals
• ATA230: Atara Biotherapeutics
• Triplex: Helocyte
• Viralym-M: AlloVir
• V160: Merck
• VBI-1501: VBI Vaccines
• HB-101 (VaxWave): Hookipa Biotech
• AVX601: AlphaVax
• CMV glycoprotein B MF59 (gB/MF59): Sanofi
• ALVAC-CMV (vCP260): Sanofi
• NPC-21: Nobelpharma
• mRNA-1647: ModernaTX
• VBI-1901: VBI Vaccines
• ITI-1001: Immunomic Therapeutics 

And several others. 

Concluding Thoughts on CMV Therapeutics Market Growth 

CMV Market Drivers are attributable to 

• Emerging Therapies- The high burden of CMV disease and morbidity makes it a right candidate for new therapies and vaccines. 
• Better Efficacy and Safety Profiles - Various pipeline molecules show better safety and promising activity than those currently being used. 
• Increased incidence and prevalence - Increased public awareness creates a lucrative opportunity for innovation of therapeutics. 
• Increased awareness - Growing R&D is increasing the demand for better diagnosis and CMV Infections treatment options. 

However, there are  CMV Market size growth Barriers that influence CMV Market growth 

• Challenges in existing therapies- Current therapies are inadequate because of severe toxicities.
• Diagnostic challenges in congenital cytomegalovirus infection- Diagnostic options are much needed to improve the CMV prognosis and outcomes for patients, as existing diagnostic options do not detect some features of congenital CMV. 
• Generic drugs of off-patent therapies- All available drugs for CMV infection have gone off-patented except one. The generic market of a drug shall affect the overall sales of the CMV market. 
• The complex mechanism of action and treatment costs- There is a lack of knowledge about the complex mechanism of action of the disease with various targets for inhibition. 
• Limitation in the current therapeutic market - One of the major unmet needs primarily in the prophylactic market is the efficacy and the viral resistance to the current drugs that is a limitation for the current therapeutic market. 

Scope of the Cytomegalovirus Infection Market

• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
• Cytomegalovirus Infection Markets Segmentation: By Geographies and By Cytomegalovirus Infection Therapies (Historical and Forecasted, Current and Upcoming)
• Leading Companies investigating its candidates for CMV Infections: Takeda/Shire Pharmaceuticals, Atara Biotherapeutics, Helocyte, AlloVir, Merck, VBI Vaccines, Hookipa Biotech, AlphaVax, Sanofi, Nobelpharma, ModernaTX, Immunomic Therapeutics, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis.
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Cytomegalovirus (CMV) Infection Therapeutics Market 

Table of Contents 

Browse detailed TOC with charts, figures, tables @ Cytomegalovirus Infection Market Size Report

Related Reports              

DelveInsight's Cytomegalovirus (CMV) Infection - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Cytomegalovirus (CMV) Infection in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Cytomegalovirus (CMV) Infection Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cytomegalovirus (CMV) Infection market. 

The comprehensive report proffers a solid foundation to advance further research and analysis into the COVID-19 covering morbidity and mortality.

DelveInsight's Hepatitis C- Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.

DelveInsight's Clostridium Difficile Infections Market Insights, Epidemiology and Forecast 2030 report provides a detailed overview of the disease & understanding of forecasted epidemiology.

DelveInsight's Influenza A Infections - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. 

DelveInsight's Nosocomial Infections Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.

DelveInsight's Aspergillosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of the Aspergillosis Market trends in 7MM.

DelveInsight's Diverticulitis Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.

DelveInsight's Genital Herpes Market Insights, Epidemiology & Forecast 2030 report gives a detailed overview of the disease and in-depth understanding of historical & forecasted epidemiology.

DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur
[email protected]
+1(919)321-6187 
DelveInsight

SOURCE DelveInsight Business Research, LLP